Patients with diabetes show poor adherence to heart disease drugs

March 1, 2020

Adherence to heart disease therapies dropped by half within one year  

This study on diabetes looked at members newly diagnosed with diabetes who also had pre-existing cardiovascular disease (ASCVD). Three separate antihyperglycemic drug classes are recommended as add-on therapy for people with diabetes who also have ASCVD. 

  • Glucagon like peptide-1 agonists (GLP-1) 
  • Sodium-glucose cotransporter-2 inhibitors (SGLT-2i
  • Dipeptidyl peptidase-4 inhibitors (DPP-4i) 

All these medications require long-term adherence to reduce complications from ASCVD. But for all the drug classes in the study, adherence dropped off by about half within a year. (Yet the drug manufacturers reported adherence of 90% in their clinical trials.)

Among Commercially Insured Members with Diabetes Mellitus (DM), Choice and Persistence of Drug Therapy: Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) Versus Glucagon-like Peptide-1 Agonists (GLP-1) or Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) ((fall 2018))

Related news

Perspectives

September 14, 2023

Cheers to 20 years and another amazing Specialty Summit!

The 20th annual Specialty Summit hosted by Prime and Magellan Rx returned to…

Perspectives

September 8, 2023

October 2023 decisions expected from the FDA

At Prime Therapeutics (Prime), we’ve positioned ourselves to best prepare our clients to…

Perspectives

August 28, 2023

Specialty Drug Pipeline Monthly Update: August 2023

This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…